Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-25-006493
Filing Date
2025-05-06
Accepted
2025-05-06 16:05:42
Documents
80
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q rigl-20250331x10q.htm   iXBRL 10-Q 2089196
2 EX-31.1 rigl-20250331xex31d1.htm EX-31.1 15792
3 EX-31.2 rigl-20250331xex31d2.htm EX-31.2 16678
4 EX-32.1 rigl-20250331xex32d1.htm EX-32.1 8970
5 GRAPHIC rigl-20250331x10q007.jpg GRAPHIC 79278
  Complete submission text file 0001558370-25-006493.txt   8691711

Data Files

Seq Description Document Type Size
6 EX-101.SCH rigl-20250331.xsd EX-101.SCH 60253
7 EX-101.CAL rigl-20250331_cal.xml EX-101.CAL 60193
8 EX-101.DEF rigl-20250331_def.xml EX-101.DEF 223110
9 EX-101.LAB rigl-20250331_lab.xml EX-101.LAB 492344
10 EX-101.PRE rigl-20250331_pre.xml EX-101.PRE 365036
83 EXTRACTED XBRL INSTANCE DOCUMENT rigl-20250331x10q_htm.xml XML 1423432
Mailing Address 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO CA 94080 650-624-1100
RIGEL PHARMACEUTICALS INC (Filer) CIK: 0001034842 (see all company filings)

EIN.: 943248524 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-29889 | Film No.: 25917207
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)